#1 Clinical Trials Search in Europe

Tenofovir Alafenamide

This article explores the use of Tenofovir Alafenamide (TAF) in clinical trials for treating chronic hepatitis B (CHB) and HIV. TAF is a newer formulation of tenofovir that offers improved efficacy and safety profiles compared to older treatments. The trials examine TAF’s effectiveness in viral suppression, liver health improvement, and reduction of side effects, particularly related to kidney function and bone density.

Table of Contents

What is Tenofovir Alafenamide (TAF)?

Tenofovir Alafenamide, commonly known as TAF, is a medication used to treat various viral infections. It’s a newer version of an older drug called Tenofovir Disoproxil Fumarate (TDF). TAF is also known by the brand name Vemlidy[1]. It’s important to note that TAF is a prodrug, which means it’s inactive when you take it but becomes active once it’s inside your body[2].

What Conditions Does TAF Treat?

TAF is primarily used to treat two main conditions:

  1. Chronic Hepatitis B (CHB): This is a long-lasting liver infection caused by the hepatitis B virus. TAF helps control the virus and prevent liver damage[1].
  2. HIV Infections: TAF is also used as part of combination therapy to treat Human Immunodeficiency Virus (HIV) infections[3].

In some cases, TAF is being studied for its potential use in treating Multiple Sclerosis (MS), particularly a type called Relapsing-Remitting Multiple Sclerosis (RRMS)[4].

How Does TAF Work?

TAF works by targeting the viruses that cause hepatitis B and HIV. Once inside your body, it becomes active and helps to:

  • Reduce the amount of virus in your body (known as viral load)
  • Prevent the virus from multiplying
  • Protect your liver cells (in the case of hepatitis B) or immune cells (in the case of HIV) from further damage

In the case of multiple sclerosis, researchers are studying whether TAF can help by targeting a virus called Epstein-Barr virus, which may play a role in MS[4].

Benefits of TAF

TAF offers several advantages over its predecessor, TDF:

  1. Lower dose: TAF is effective at a much lower dose (25 mg) compared to TDF (300 mg). This means less medication in your body to achieve the same effect[3].
  2. Better kidney safety: TAF appears to be safer for your kidneys. Studies have shown that patients who switch from TDF to TAF often see improvements in their kidney function[2].
  3. Better bone safety: TAF is also gentler on your bones. Patients taking TAF are less likely to experience bone loss compared to those taking TDF[5].
  4. Effective viral suppression: TAF is just as effective as TDF in reducing the amount of virus in your body, whether you have hepatitis B or HIV[5].

Safety Profile

While TAF is generally considered safer than TDF, especially for your kidneys and bones, it’s still important to be aware of potential side effects and safety considerations:

  • Your doctor will monitor your kidney function and bone density while you’re taking TAF[5].
  • If you have hepatitis B, your liver function will be closely monitored[6].
  • Common side effects may include nausea, headache, and fatigue, but these are usually mild[4].
  • Always inform your doctor about any other medications you’re taking, as TAF can interact with certain drugs.

Ongoing Research

Scientists are continually studying TAF to understand its full potential and long-term effects. Some areas of ongoing research include:

  • Using TAF to treat hepatitis B patients who currently don’t meet the criteria for treatment under current guidelines[7].
  • Investigating whether TAF can help reverse liver fibrosis (scarring) in patients with chronic hepatitis B[6].
  • Studying the effectiveness of TAF in treating multiple sclerosis[4].
  • Comparing the long-term safety and effectiveness of TAF to other antiviral medications[2].

Remember, while TAF is a promising medication, it’s important to take it exactly as prescribed by your doctor and attend all follow-up appointments to monitor your progress and any potential side effects.

Aspect Details
Primary Focus Evaluating Tenofovir Alafenamide (TAF) in treating chronic hepatitis B and HIV
Key Advantages Higher intracellular drug concentration, lower dosing, potentially fewer side effects
Main Study Objectives Viral suppression, liver health improvement, kidney function preservation, bone density effects
Patient Groups Treatment-naive, those with mild liver enzyme elevation, patients with renal impairment, individuals switching from other antivirals
Comparison Often compared to Tenofovir Disoproxil Fumarate (TDF) or other standard treatments
Duration of Studies Varies, ranging from 48 weeks to several years
Key Outcomes Measured HBV DNA levels, ALT normalization, HBeAg loss/seroconversion, eGFR changes, bone mineral density changes
Potential Impact May expand treatment options for patients not meeting current antiviral therapy guidelines

FAQ

  • What is Tenofovir Alafenamide (TAF)? Tenofovir Alafenamide (TAF) is a newer formulation of tenofovir, an antiviral medication used to treat chronic hepatitis B (CHB) and HIV. It is designed to have higher intracellular active drug concentration, allowing for lower dosing and potentially reducing side effects compared to older formulations.
  • How does TAF compare to Tenofovir Disoproxil Fumarate (TDF)? TAF has shown similar efficacy to TDF in viral suppression but with improved safety profiles. Studies indicate that TAF may have less impact on kidney function and bone mineral density compared to TDF, making it a potentially safer option for long-term treatment.
  • What are the main goals of the clinical trials using TAF? The main goals include evaluating TAF's effectiveness in suppressing hepatitis B virus (HBV) or HIV, improving liver health in CHB patients, assessing its impact on kidney function and bone density, and comparing its overall safety profile to other treatments.
  • Who are the target patients for these TAF clinical trials? The trials target various groups, including treatment-naive CHB patients, those with mildly elevated liver enzymes, patients with renal impairment, and individuals switching from other antiviral medications. Some studies also focus on HIV patients.
  • What are the potential benefits of using TAF over other treatments? Potential benefits of TAF include effective viral suppression, improved liver health, reduced risk of kidney-related side effects, better bone mineral density preservation, and the possibility of expanding treatment to patients who may not meet current guidelines for antiviral therapy.

Ongoing Clinical Trials on Tenofovir Alafenamide

  • Study on Switching HIV Treatment to Doravirine and Islatravir for Patients with HIV-1

    Not yet recruiting

    1 1 1
    Investigated drugs:
    France Germany Italy Spain

  • Study of Tenofovir Alafenamide for Children and Teens with Chronic Hepatitis B

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Romania

  • Phase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus

    Not recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Czechia Hungary Poland Portugal Slovakia +1

  • Study on the Safety and Effectiveness of Emtricitabine and Tenofovir Alafenamide for HIV-1 Prevention in Men and Transgender Women at Risk

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Austria Denmark France Germany Ireland Italy +1

  • Study on the Effects of Ianalumab in Patients with Sjögren’s Syndrome

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Weekly Oral GS-1720 and GS-4182 for Untreated HIV-1 Patients

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany Poland Portugal Romania Spain

  • Study on Stopping Tenofovir Alafenamide, Tenofovir Disoproxil, and Entecavir in Patients with Chronic Hepatitis B

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on Dolutegravir and Lamivudine for Maintaining Viral Control in Children with HIV Aged 2 to Under 15 Years

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • Study Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Germany The Netherlands Poland Spain

  • Study to Compare Weekly Islatravir/Lenacapavir with Bictegravir/Emtricitabine/Tenofovir in People with HIV-1 Who Are Virologically Suppressed

    Not recruiting

    1 1 1
    Investigated drugs:
    France Germany Spain

Glossary

  • Tenofovir Alafenamide (TAF): A newer formulation of tenofovir, an antiviral medication used to treat chronic hepatitis B and HIV. It has higher intracellular active drug concentration, allowing for lower dosing and potentially fewer side effects.
  • Chronic Hepatitis B (CHB): A long-term liver infection caused by the hepatitis B virus that can lead to serious liver damage, cirrhosis, and liver cancer if left untreated.
  • HIV: Human Immunodeficiency Virus, a virus that attacks the body's immune system and can lead to AIDS if not treated.
  • Viral Suppression: The reduction of virus levels in the body to very low or undetectable levels through treatment.
  • ALT (Alanine Aminotransferase): An enzyme found primarily in the liver. Elevated levels can indicate liver damage or disease.
  • eGFR (estimated Glomerular Filtration Rate): A measure of kidney function that estimates how well the kidneys are filtering waste from the blood.
  • Bone Mineral Density (BMD): A measurement of the amount of calcium and other minerals in bones, used to assess bone strength and the risk of fractures.
  • HBeAg: Hepatitis B e-antigen, a protein produced by the hepatitis B virus. Its presence in the blood indicates that the virus is actively replicating.
  • Cirrhosis: Advanced scarring of the liver caused by long-term liver damage, which can impair liver function.
  • Fibrosis: The formation of scar tissue in the liver as a result of chronic liver disease or injury.

References

  1. https://clinicaltrials.gov/study/NCT03559790
  2. https://clinicaltrials.gov/study/NCT02957864
  3. https://clinicaltrials.gov/study/NCT00036634
  4. https://clinicaltrials.gov/study/NCT04880577
  5. https://clinicaltrials.gov/study/NCT03471624
  6. https://clinicaltrials.gov/study/NCT04939441
  7. https://clinicaltrials.gov/study/NCT03753074